Free Trial

Perrigo (PRGO) Stock Price, News & Analysis

$28.11
+0.04 (+0.14%)
(As of 07/26/2024 ET)
Today's Range
$27.91
$28.37
50-Day Range
$25.43
$29.72
52-Week Range
$24.82
$40.28
Volume
786,338 shs
Average Volume
1.71 million shs
Market Capitalization
$3.83 billion
P/E Ratio
N/A
Dividend Yield
3.91%
Price Target
$39.33

Perrigo MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
39.9% Upside
$39.33 Price Target
Short Interest
Healthy
4.36% of Shares Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-1.93
Upright™ Environmental Score
News Sentiment
0.27mentions of Perrigo in the last 14 days
Based on 8 Articles This Week
Insider Trading
Acquiring Shares
$27,900 Bought Last Quarter
Proj. Earnings Growth
25.78%
From $2.56 to $3.22 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.96 out of 5 stars

Medical Sector

6th out of 936 stocks

Pharmaceutical Preparations Industry

1st out of 436 stocks

PRGO stock logo

About Perrigo Stock (NYSE:PRGO)

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

PRGO Stock Price History

PRGO Stock News Headlines

Perrigo (PRGO) Set to Announce Earnings on Friday
The next companies to potentially benefit thanks to Nvidia are …
Nvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And it’s enlisting a whole new set of partners.
Perrigo (NYSE:PRGO) Lowered to "Hold" at StockNews.com
O'Keefe Stevens Advisory Q2 2024 Investor Letter
The next companies to potentially benefit thanks to Nvidia are …
Nvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And it’s enlisting a whole new set of partners.
Perrigo Q1 Earnings Surpass, Sales Miss Estimates
See More Headlines
Receive PRGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Perrigo and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/04/2024
Ex-Dividend for 6/18 Dividend
5/31/2024
Dividend Payable
6/18/2024
Today
7/26/2024
Next Earnings (Confirmed)
8/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
CUSIP
71429010
Employees
9,140
Year Founded
1887

Price Target and Rating

Average Stock Price Target
$39.33
High Stock Price Target
$42.00
Low Stock Price Target
$35.00
Potential Upside/Downside
+39.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-12,700,000.00
Pretax Margin
-2.44%

Debt

Sales & Book Value

Annual Sales
$4.66 billion
Cash Flow
$5.30 per share
Book Value
$35.19 per share

Miscellaneous

Free Float
135,366,000
Market Cap
$3.83 billion
Optionable
Optionable
Beta
0.51

Social Links

The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

PRGO Stock Analysis - Frequently Asked Questions

How have PRGO shares performed this year?

Perrigo's stock was trading at $32.18 at the beginning of the year. Since then, PRGO shares have decreased by 12.6% and is now trading at $28.11.
View the best growth stocks for 2024 here
.

How were Perrigo's earnings last quarter?

Perrigo Company plc (NYSE:PRGO) released its earnings results on Saturday, May, 4th. The company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.23 by $0.06. Perrigo's quarterly revenue was down 8.4% compared to the same quarter last year.
Read the conference call transcript
.

What is Murray S. Kessler's approval rating as Perrigo's CEO?

38 employees have rated Perrigo Chief Executive Officer Murray S. Kessler on Glassdoor.com. Murray S. Kessler has an approval rating of 83% among the company's employees.

Does Perrigo have any subsidiaries?

The following companies are subsidiaries of Perrigo: HRA Pharma, Ranir, Laboratoire de la Mer SAS, Geiss Destin & Dunn, ScarAway, Omega Pharma, Elan Corporation, and more.

Who are Perrigo's major shareholders?

Perrigo's top institutional investors include Bank of New York Mellon Corp (0.80%), Allspring Global Investments Holdings LLC (0.48%), Nisa Investment Advisors LLC (0.20%) and Retirement Systems of Alabama (0.12%). Insiders that own company stock include Svend Andersen, Geoffrey M Parker, James E Dillard III, Robert Willis, Patrick Lockwood-Taylor, Ronald Craig Janish, Alison Ives, Grainne Quinn, Eduardo Guarita Bezerra, Thomas Farrington, Murray S Kessler, Raymond Silcock, Bradley A Alford, Todd W Kingma and Rolf A Classon.
View institutional ownership trends
.

How do I buy shares of Perrigo?

Shares of PRGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Perrigo own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Perrigo investors own include Teva Pharmaceutical Industries (TEVA), Gilead Sciences (GILD), Mylan (MYL), AbbVie (ABBV), Allergan (AGN), Intel (INTC) and Johnson & Johnson (JNJ).

This page (NYSE:PRGO) was last updated on 7/26/2024 by MarketBeat.com Staff

From Our Partners